[go: up one dir, main page]

CY1113368T1 - Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης - Google Patents

Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης

Info

Publication number
CY1113368T1
CY1113368T1 CY20121100897T CY121100897T CY1113368T1 CY 1113368 T1 CY1113368 T1 CY 1113368T1 CY 20121100897 T CY20121100897 T CY 20121100897T CY 121100897 T CY121100897 T CY 121100897T CY 1113368 T1 CY1113368 T1 CY 1113368T1
Authority
CY
Cyprus
Prior art keywords
thiazolo
deoxy
acetyl
beta
amino
Prior art date
Application number
CY20121100897T
Other languages
English (en)
Inventor
David Kucera
Gregory J Haley
Erik J Rueden
Tingman Wang
Martin Viertelhaus
Fritz Blatter
Original Assignee
Anadys Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals, Inc. filed Critical Anadys Pharmaceuticals, Inc.
Publication of CY1113368T1 publication Critical patent/CY1113368T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα αποκάλυψη αφορά σε άλας π-τολούολο σουλφονικού οξέος της 5-αμινο-3-(2'-O-ακετυλ-3'-δεοξυ-βητα-D-ριβοφουρανοζυλ)-3Η-θειαζολο[4,5-d]πυριμιδιν-2-όνης και χρήση αυτού στη θεραπεία καταστάσεων όπως ιικών μολύνσεων, όγκων και καρκίνων. Επίσης αποκαλυπτόμενη είναι μια μέθοδος παρασκευής του άλατος π-τολούολο σουλφονικού οξέος της 5-αμινο-3-(2'-O-ακετυλ-3'-δεοξυ-βητα-D-ριβοφουρανοζυλ)-3Η-θειαζολο[4,5-d]πυριμιδιν-2-όνης και μέθοδοι για παρασκευή ενώσεων φουρανόζης, οι οποίες είναι χρήσιμα ενδιάμεσα στην παρασκευή φαρμακευτικών ενώσεων, όπως άλατος π-τολούολο σουλφονικού οξέος της 5-αμινο-3-(2'-O-ακετυλ-3'-δεοξυ-βητα-D-ριβοφουρανοζυλ)-3Η-θειαζολο[4,5-d]πυριμιδιν-2-όνης και των παρομοίων.
CY20121100897T 2006-10-17 2012-09-28 Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης CY1113368T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85200206P 2006-10-17 2006-10-17
US89940507P 2007-02-05 2007-02-05
US95359707P 2007-08-02 2007-08-02
EP07873546A EP2076132B1 (en) 2006-10-17 2007-10-16 P-toluene sulfonic acid salt of 5-amino-3-(2'-o-acetyl-3'-deoxy-beta -d-ribofuranosyl)-3h-thiazole [4, 5-d]pyrimidine-2-one and methods for preparation

Publications (1)

Publication Number Publication Date
CY1113368T1 true CY1113368T1 (el) 2016-06-22

Family

ID=39472747

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100897T CY1113368T1 (el) 2006-10-17 2012-09-28 Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης

Country Status (24)

Country Link
US (2) US7928085B2 (el)
EP (1) EP2076132B1 (el)
JP (2) JP5279715B2 (el)
KR (2) KR101486444B1 (el)
AR (1) AR063484A1 (el)
AU (1) AU2007353381B2 (el)
BR (1) BRPI0717741A2 (el)
CA (2) CA2898225A1 (el)
CY (1) CY1113368T1 (el)
DK (1) DK2076132T3 (el)
DO (1) DOP2007000131A (el)
EA (1) EA017005B1 (el)
ES (1) ES2390930T3 (el)
IL (2) IL198180A (el)
MX (1) MX2009004028A (el)
MY (1) MY150408A (el)
NO (1) NO20091598L (el)
NZ (1) NZ576408A (el)
PE (1) PE20081105A1 (el)
PL (1) PL2076132T3 (el)
PT (1) PT2076132E (el)
TW (1) TWI415854B (el)
UY (1) UY30650A1 (el)
WO (1) WO2008140549A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2034834B1 (en) 2006-06-22 2011-01-26 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-beta-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
US20110166092A1 (en) * 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
PE20170679A1 (es) 2014-12-08 2017-05-22 Hoffmann La Roche Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CR20170424A (es) 2015-03-16 2018-01-26 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
JP6779232B2 (ja) 2015-05-08 2020-11-04 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体
EP3294746B1 (en) 2015-05-12 2021-10-06 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
WO2017001307A1 (en) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
US11142534B2 (en) * 2017-01-06 2021-10-12 Hoffmann-La Roche Inc. Process for the preparation of 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
CN110007010A (zh) * 2018-01-05 2019-07-12 大鹏药品工业株式会社 源自曲氟尿苷的类似物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224081A (ja) * 1994-02-10 1995-08-22 Kobayashi Koryo Kk デオキシリボフラノシルハライド誘導体の製造方法
US5532374A (en) * 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JP4067226B2 (ja) * 1999-04-01 2008-03-26 三井化学株式会社 1―ハロゲノ−2−デオキシリボフラノース誘導体の製造方法
JP2000327693A (ja) * 1999-05-21 2000-11-28 Mitsui Chemicals Inc 2’−デオキシ−β−シチジン誘導体の製造方法
US6649761B2 (en) * 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
MXPA04004966A (es) * 2001-11-27 2006-03-21 Anadys Pharmaceuticals Inc Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EA200600540A1 (ru) * 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с
EP1758916B1 (en) * 2004-06-07 2012-11-21 Anadys Pharmaceuticals, Inc. 3-BETA-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
BRPI0518861B8 (pt) * 2004-12-17 2021-05-25 Anadys Pharmaceuticals Inc compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e uso de quantidade terapeutica ou profilaticamente eficaz de composto ou de composição farmacêutica
US7501526B2 (en) * 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
EP2034834B1 (en) * 2006-06-22 2011-01-26 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-beta-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
KR101266843B1 (ko) * 2006-12-08 2013-05-24 가부시키가이샤 에이피아이 코포레이션 퓨라노스 유도체의 제조방법

Also Published As

Publication number Publication date
JP5279715B2 (ja) 2013-09-04
IL198180A0 (en) 2009-12-24
US7928085B2 (en) 2011-04-19
NO20091598L (no) 2009-07-10
ES2390930T3 (es) 2012-11-19
JP5703334B2 (ja) 2015-04-15
IL223126A (en) 2016-08-31
US20110172447A1 (en) 2011-07-14
NZ576408A (en) 2012-04-27
JP2013166782A (ja) 2013-08-29
KR101486444B1 (ko) 2015-01-26
PT2076132E (pt) 2012-10-03
TWI415854B (zh) 2013-11-21
JP2010506947A (ja) 2010-03-04
MX2009004028A (es) 2009-05-11
KR101515077B1 (ko) 2015-04-24
AU2007353381A1 (en) 2008-11-20
EA017005B1 (ru) 2012-09-28
KR20090074237A (ko) 2009-07-06
EP2076132A4 (en) 2011-05-04
CA2666537C (en) 2015-12-08
AU2007353381B2 (en) 2013-07-04
KR20140119203A (ko) 2014-10-08
DK2076132T3 (da) 2012-09-10
CA2898225A1 (en) 2008-11-20
IL198180A (en) 2015-06-30
WO2008140549A1 (en) 2008-11-20
PL2076132T3 (pl) 2013-01-31
CA2666537A1 (en) 2008-11-20
PE20081105A1 (es) 2008-08-15
HK1132429A1 (en) 2010-02-26
AR063484A1 (es) 2009-01-28
US20090197826A1 (en) 2009-08-06
TW200833699A (en) 2008-08-16
BRPI0717741A2 (pt) 2014-04-08
MY150408A (en) 2014-01-15
DOP2007000131A (es) 2008-09-15
EP2076132B1 (en) 2012-07-11
EP2076132A1 (en) 2009-07-08
EA200970387A1 (ru) 2009-10-30
UY30650A1 (es) 2008-05-31
US8193342B2 (en) 2012-06-05
IL223126A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
CY1113368T1 (el) Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
CY1123817T1 (el) Μεθοδος για την παρασκευη ενωσεων που ειναι χρησιμες ως αναστολεις sglt
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
CY1121202T1 (el) ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b)]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΗΣ JANUS
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
CY1108186T1 (el) Παραγωγα κουιναζολινης ως αναστολεις της κινασης τυροσινης
CY1110669T1 (el) Χρησιμοποιηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη θεραπευτικη αγωγη της καταθλιψης
CY1113647T1 (el) Αναλογα καρβα-νουκλεοσιδιου για αντι-ιικη θεραπεια
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
CY1108415T1 (el) Παραγωγα 4-αμινοπιπεριδινης και η χρησιμοποιηση αυτων ως φαρμακων
CY1117319T1 (el) Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης
CY1113354T1 (el) Αναστολεις φωσφορυλασων και νουκλεοζιδασων νουκλεοζιδιου
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
CY1113538T1 (el) Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου
EA200200249A1 (ru) Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
EP1720556A4 (en) NEW 2'-C-METHYL-NUCLEOSIDE DERIVATIVES
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
CY1110457T1 (el) Παραγωγα της πυριδο[2,3-d]πυριμιδινης, η παρασκευη τους και η εφαρμογη τους σε θεραπευτικες αγωγες